RK-805, an endothelial-cell-growth inhibitor produced by Neosartorya sp., and a docking model with methionine aminopeptidase-2

被引:25
作者
Asami, Y
Kakeya, H
Onose, R
Chang, YH
Toi, M
Osada, H
机构
[1] RIKEN, Discovery Res Inst, Antibiot Lab, Wako, Saitama 3510198, Japan
[2] Saitama Univ, Grad Sch Sci & Engn, Saitama, Saitama 3388570, Japan
[3] St Louis Univ, Sch Med, Hlth Sci Ctr, St Louis, MO 63104 USA
[4] Tokyo Metropolitan Komagome Hosp, Bunkyo Ku, Tokyo 1138677, Japan
关键词
angiogenesis inhibitor; microbial metabolites; endothelial cells; methionine aminopeptidase-2; docking model;
D O I
10.1016/j.tet.2003.09.104
中图分类号
O62 [有机化学];
学科分类号
070303 ; 081704 ;
摘要
We found that a fungus Neosartorya sp. produced an angiogenesis inhibitor, RK-805. By spectroscopic analyses and semisynthetic methods from fumagillin, the structure of RK-805 was identified as 6-oxo-6-deoxyfumagillol, which has not been reported as a natural product. RK-805 preferentially inhibited the growth of human umbilical vein endothelial cells (HUVECs) rather than that of human normal fibroblast in cell proliferation assays and blocked endothelial cell migration induced by vascular endothelial growth factor (VEGF). Moreover, RK-805 selectively inhibited methionine aminopeptidase-2 (MetAP2), but not methionine aminopeptidase-1 (MetAP1). The docked structure of RK-805 complexed with human MetAP2 indicated that not only a covalent bond between a nucleophilic imidazole nitrogen atom of His231 and the carbon of the reactive spirocyclic epoxide of RK-805, but also a hydrogen bond between NH (Asn329) and the carbonyl group of RK-805 at C-6 promote close contact in the binding pocket of the enzyme. Taken together, these results suggest that structure activity relationships of RK-805 derivatives at both C-4 and C-6, in comparison with ovalicin and TNP-470, would be useful for development of new angiogenesis inhibitors. (C) 2004 Elsevier Ltd. All rights reserved.
引用
收藏
页码:7085 / 7091
页数:7
相关论文
共 37 条
  • [1] EUKARYOTIC METHIONYL AMINOPEPTIDASES - 2 CLASSES OF COBALT-DEPENDENT ENZYMES
    ARFIN, SM
    KENDALL, RL
    HALL, L
    WEAVER, LH
    STEWART, AE
    MATTHEWS, BW
    BRADSHAW, RA
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1995, 92 (17) : 7714 - 7718
  • [2] Azaspirene:: A novel angiogenesis inhibitor containing a 1-oxa-7-azaspiro[4.4]non-2-ene-4,6-dione skeleton produced by the fungus Neosartotya sp.
    Asami, Y
    Kakeya, H
    Onose, R
    Yoshida, A
    Matsuzaki, H
    Osada, H
    [J]. ORGANIC LETTERS, 2002, 4 (17) : 2845 - 2848
  • [3] PROCESSING OF THE INITIATION METHIONINE FROM PROTEINS - PROPERTIES OF THE ESCHERICHIA-COLI METHIONINE AMINOPEPTIDASE AND ITS GENE STRUCTURE
    BENBASSAT, A
    BAUER, K
    CHANG, SY
    MYAMBO, K
    BOOSMAN, A
    CHANG, S
    [J]. JOURNAL OF BACTERIOLOGY, 1987, 169 (02) : 751 - 757
  • [4] Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors
    Bergers, G
    Song, S
    Meyer-Morse, N
    Bergsland, E
    Hanahan, D
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 2003, 111 (09) : 1287 - 1295
  • [5] STRUCTURE OF OVALICINE
    BOLLINGE.P
    SIGG, HP
    WEBER, HP
    [J]. HELVETICA CHIMICA ACTA, 1973, 56 (03) : 819 - 830
  • [6] CHANG YH, 1990, J BIOL CHEM, V265, P19892
  • [7] Angiogenesis modulation in cancer research: Novel clinical approaches
    Cristofanilli, M
    Charnsangavej, C
    Hortobagyi, GN
    [J]. NATURE REVIEWS DRUG DISCOVERY, 2002, 1 (06) : 415 - 426
  • [8] THALIDOMIDE IS AN INHIBITOR OF ANGIOGENESIS
    DAMATO, RJ
    LOUGHNAN, MS
    FLYNN, E
    FOLKMAN, J
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1994, 91 (09) : 4082 - 4085
  • [9] Inhibition of angiogenesis: Treatment options for patients with metastatic prostate cancer
    Figg, WD
    Kruger, EA
    Price, DK
    Kim, S
    Dahut, WD
    [J]. INVESTIGATIONAL NEW DRUGS, 2002, 20 (02) : 183 - 194
  • [10] The rationale and future potential of angiogenesis inhibitors in neoplasia
    Gasparini, G
    [J]. DRUGS, 1999, 58 (01) : 17 - 38